MedTrace Logo

This is a Single Center, Open-label Prospective Study to Evaluate the Effect of Xiidra® (Lifitegrast Ophthalmic Solution 5.0%) on Tear Film Biomarkers in Dry Eye

NCT07490535 · Status: NOT_YET_RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2026-03-24

No results posted yet for this study

Summary

This is a single-center prospective open-label, clinical trial to explore proteomic expression of tear fluid biomarkers in patients with dry eye treated with Lifitegrast.

Conditions

  • Ocular Surface Disease
  • Dry Eye Syndrome (DES)

Interventions

DRUG

(Xiidra®) Lifitegrast Ophthalmic Solution 5.0%

30 DED subjects will receive (Xiidra®) lifitegrast ophthalmic solution 5.0%

Sponsors & Collaborators

  • Bausch & Lomb Incorporated

    collaborator INDUSTRY

  • Pittsburgh Research Institute

    lead OTHER

Principal Investigators

  • Leanne T Labriola, DO, MBA · Pittsburgh Research Institute

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-03-31
Primary Completion
2026-09-30
Completion
2026-11-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07490535 on ClinicalTrials.gov